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Hypercholesterolemia, homocysteine, oxidative stress, and hyperglycemia have been recognized as the major risk factors for
atherogenesis. Their impact on the physiology and biochemistry of vascular cells has been widely demonstrated for the last
century. However, the recent discovery of the role of epigenetics in human disease has opened up a new ﬁeld in the study of
atherogenic factors. Thus, epigenetic tags in endothelial, smooth muscle, and immune cells seem to be diﬀerentially aﬀected by
similar atherogenic stimuli. This paper summarizes some recent works on expression of histone-modifying enzymes and DNA
methylation directly linked to the presence of risk factors that could lead to the development or prevention of the atherosclerotic
process.
1.Introduction
Cardiovascular-related diseases are the most serious threat
to human health that authorities will have to manage
worldwide. All of these pathological outcomes, like stroke,
thrombosis, or infarction, are pathological events result-
ing from the long-lasting and silent process, known as
atherosclerosis [1]. Atherosclerosis is considered to be a
multifactorial pathology where preferential zones within the
arteries, such as branches and curvatures, are prone to
diﬀerential expression of genes with a proatherosclerotic
proﬁle, serving as potential substratum for lesions when
risk factors are introduced [2, 3]. In this sense epigenetics,
deﬁned as the structural adaptation of chromosomal regions
so as to register, signal, or perpetuate altered gene activity
states [4] might play a signiﬁcant role in the pathogenicity
of cardiovascular risk factors, which could explain the
speciﬁcity in the establishment and further development of
the atherosclerotic lesion.
2. Atherosclerosis Overview
Atherosclerosis is a progressive disease characterized by the
accumulation of lipids and ﬁbrous elements in susceptible
zones in the large and medium arteries [5]. Normal arteries
are characterized by one internal or luminal surface of
nonadherent endothelial cells (ECs) over a layer of extra-
cellular matrix (ECM), mainly formed by collagen and
proteoglycans, followed by a media layer of smooth muscle
cells (SMC) and an external adventitia layer. Diverse stimuli,
such as hypercholesterolemia, smoking, or hypertension,
lead to a pathological activation of EC, attracting blood
monocytes into the intima layer, where they diﬀerentiate
into macrophages in order to remove cholesterol accu-
mulated in this layer. Monocyte chemoattractant protein-
1 (MCP-1) appears responsible for the direct migration of
monocytes into the intima at sites of lesion formation, and
macrophage colony-stimulating factor (M-CSF) contributes
to the diﬀerentiation of monocytes into macrophages
[6], while vascular cell adhesion molecule-1 (VCAM-1)
expressed earlier on endothelial surface binds monocytes
and T lymphocytes [7]. The by-products of cholesterol-
loaded macrophages attract other immune cells and pro-
mote the phenotypic switching of SMC, transforming them
from a “contractile” to a “synthetic” phenotype [8]. Early
atherosclerotic lesions can be found even in the fetal
aorta, enhanced greatly by maternal hypercholesterolemia
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3. StructuralEpigeneticModiﬁcations on
the Chromatin
In eukaryotes, the protection and packaging of the genetic
material are largely performed by the histone proteins,
which also oﬀer a scaﬀold for regulating processes such as
transcription, replication, and repair of DNA [10]. Chro-
matin,theDNA-nucleosomepolymer,isadynamicmolecule
existing in many conﬁgurations between heterochromatin,
highlycompactedandsilenced chromatin, and euchromatin,
transcriptionally active open chromatin [11]. The basic
chromatin unit or nucleosome consists of a protein octamer
containing two molecules of each canonical histone (H2A,
H2B, H3, and H4), around which is wrapped 147 base
pairs of DNA (Figure 1). Nucleosomes may be irregularly
packed and fold into higher-order structures that occur in
diverse regions of the genome during cell-fate speciﬁcation
or in distinct stages of the cell cycle. The arrangement
of nucleosomes can be altered by covalent modiﬁcation
of histones, which can include acetylation, methylation,
phosphorylation, ubiquitination, and sumoylation. Post-
translational modiﬁcations of these proteins are facilitated
by diﬀerent enzymes, whose activities are regulated by
other speciﬁc modulators. Although the enzymes involved in
histone modiﬁcations are sequence-speciﬁc surrounding the
target amino acid residue, it is widely believed that they may
possess substrates outside the histone molecules [12].
Acetylated-lysines in histone 3 (H3) and histone 4
(H4) associated with active transcription are the result of
the interplay between histone acetylases and deacetylases
(Figure 2). Histone acetyltransferase (HAT; EC 2.3.1.48)
catalyzes the transfer of an acetyl group from acetyl-
CoA to speciﬁc lysines in histone. Transcription coac-
tivators, like p300/Creb-Binding Protein (PCAF), display
acetyltransferase activity [13] . Histone deacetylase (HDAC;
EC 3.5.1.98) comprises a range of isoenzymes responsible
for catalyzing the removal of acetyl groups from lysine
residues of histones. They are classiﬁed as class I, II, or
III according to homologous sequence domains. HDAC
activity is inhibited by butyrate, trichostatin A (TSA), and
suberoylanilide hydroxamic acid (SAHA), with the list of
HDAC inhibitors growing due to the increasing interest in
their eﬀects in a clinical setting as anticancer drugs [14]. TSA
is the most potent HDAC inhibitor known to date and is
frequently used in studies on the role of histone acetylation
in gene expression. Although it has been approved the use of
some HDAC inhibitors in cancer therapy, the major concern
is their lack of speciﬁcity [15].
Histone methylation is also a major dynamic covalent
epigenetic modiﬁcation (Figure 2) .T h el y s i n er e s i d u em o d -
iﬁed can be mono-, di-, or trimethylated and, depending on
thepositioninthehistonechain,methylatedlysinesareasso-
ciated with transcriptional activation or gene suppression.
Histone-lysine N-methyltransferase (HMTase, EC. 2.1.1.43)
catalyzes the transfer of a methyl group from S-adenosyl-
L-methionine to a lysine residue either on H3 or H4, while
histone demethylases eliminate methyl groups [16].
Ontheotherhand,DNAitselfcanbemodiﬁedcovalently
by methylation at the cytosine residue of CpG dinucleotides,
which commonly leads to suppression of gene expression
when occurring in a regulatory region [11]. DNA methyla-
tionatthepromoterregioncancontrolgenetranscriptionby
recruiting methylcytosine-binding proteins (MBPs) which
recognize methylated DNA sequences. Thus, DNA methyl-
transferases (DNMT, EC 2.1.1.37) catalyze the transfer of
methyl groups to DNA from S-adenosylmethionine (SAM).
DNMT can be grouped into four distinct families based
on sequence homology within their C-terminal catalytic
domains: DNMT1, DNMT2, and DNMT3 families and
the chromomethylase family, unique to the plant kingdom
[17]. In mammals, DNMT1 is the maintenance methyl-
transferase, which preferentially methylates hemimethylated
double-stranded DNA, whereas DNMT3 is known as the
de novo methyltransferase, which methylates unmethylated
or hemimethylated double-stranded DNA. The mammalian
genome encodes two functional cytosine methyltransferases
of the DNMT3 family, DNMT3A and DNMT3B, and a
third homologue, DNMT3L, which lacks cytosine methyl-
transferase activity and functions as a regulatory factor in
germ cells. DNMT3A and DNMT3B are expressed in a
range of adult tissues but at lower levels than DNMT1
[17].
4. Main Proatherogenic Risk Factors and
Epigenetic-AssociatedMechanisms
Atherosclerosis is a complex disease caused by both
genetic and environmental factors. More than one hundred
atherosclerosis-related genes have been discovered through
diﬀerent approaches such as genetically modiﬁed organisms
(apoE or LDL receptor knockout mice) or nutritional
overload (fat-feeding). Many of the genes encode for coag-
ulation factors, apolipoproteins and lipoprotein receptors,
the blood pressure axis, ECM proteases, and inﬂammatory
modulators, among others [18–20]. However, the estab-
lishment of a proatherogenic proﬁle is strongly correlated
with the presence of one or more risk factors, including
cholesterol,homocysteine,oxidativestress,anddiabetes.The
molecular eﬀects of these risk factors on EC, SMC, and
monocyte/macrophages have been widely studied; however
the study of the eﬀects on histone or DNA modiﬁcations is
still growing.
4.1. Cholesterol. The causal relationship between hyperc-
holesterolemia and atherosclerosis was identiﬁed over 100
yearsago ,butevidencewasnotclearenoughtobeconsidered
by physicians until three or four decades ago (reviewed
in [21] ). The discovery of the plasma cholesterol-carriers
(i.e., lipoproteins) and the association of diﬀerent kinds of
lipoproteins with cardiovascular disease development was a
major milestone in the atherosclerosis research ﬁeld. Thus,
both elevated low-density lipoprotein (LDL) and reduced
high-density lipoprotein (HDL) lead to an enhanced risk
of coronary heart disease. A comparative evaluation of the
two risk factors in the Atherosclerosis Risk in communities
(ARIC) study supports the idea that the degree of coronary




























Figure 1: The basic chromatin unit or nucleosome consists of a protein octamer containing two molecules of each histone (H2A, H2B, H3









Figure 2: Main posttranslational modiﬁcations occurring on His-
tone 3 and 4 are the result of dynamic activity of diﬀerent enzymes.
HAT: histone acetyl transferase; HDAC: histone deacetylase; HMT:
histone methyl transferase; (CH3)1−3: Lys can be mono-, di, or
trimethylated
In an in vivo model, Alkemade et al. [23] demonstrated
that both in utero programming and diet-induced hyper-
cholesterolemia aﬀected histone methylation modiﬁcations
and expression of accompanying lysine methyltransferases
in vascular EC and SMC, in 20-week old female apoE+/−
mouse oﬀspring from apoE
−/− and wild-type mothers.
Furthermore, these epigenetic modiﬁcations were diﬀerent
in each cell type, which suggest cell-speciﬁc epigenetic eﬀects
in response to a similar stimuli [23].
4.2. Homocysteine. Homocysteine is a nonessential sulfur-
containing amino acid involved in methionine metabolism
that has been gaining greater interest during the last four
decades due to its association with cardiovascular diseases
[24, 25]. The pathogenetic mechanism for hyperhomo-
cysteinemia is complex, since it requires the coexistence
of genetic defects of the enzymes in the homocysteine-
methionine metabolic pathway and a disturbed nutritional
state regarding folic acid, vitamin B12, and vitamin B6,
which act as cofactors of the enzymes regulating the
metabolism of homocysteine [26–28].
Hyperhomocysteinemiahasbeenassociatedwithaglobal
r e d u c t i o ni ng e n o m i cD N Am e t h y l a t i o n ,a sw e l la sad o w n -
regulation of the intracellular SAM/S-adenosylhomocysteine
(SAH) ratio, which is a marker of the methylation status
of the cell [29]. In addition, an increase in DNMT3A and
DNMT3B has been reported in SMC as a compensatory
mechanism, since SAH inhibits SAM-dependent methyl-
transferases. DNA hypomethylation has been found on
the cyclin A promoter of EC in the presence of 50uM
homocysteine, which leads to decreased binding of MeCP2
and increased binding of acetylated H3 and H4 to the cyclin
Ap r o m o t e ri nE C[ 30]. On the other hand, some critical
promoter regions, such as PPARα and PPARγ,u n d e r g o
cytosine methylation when human monocytes are incubated
with higher levels of homocysteine [31].
4.3. Inﬂammation. Inﬂammation plays a central role in all
phases of the atherosclerotic process [6]. T cells, monocytes-
macrophages, and chemokines are the immune components
involved in the formation of the atherosclerotic lesion. Thus,
bindingofmonocytestoECandSMCrepresentsakeystepin
the pathogenesis of inﬂammation and atherosclerosis as well
as antigen presentation by macrophages to T lymphocytes
[6].
Most of the cytokines and chemokines are regulated
by the nuclear factor kappa B transcription factor (NFκB).
NFκB in the latent form exists in the cytoplasm of unstim-
ulated cells comprising a transcriptionally active dimer
bound to an inhibitor protein, IkB. The currently known
subunit members of the NFκB family in mammals are
p50, p65 (RelA), c-Rel, p52, and RelB [32]. Both VCAM-
1 and MCP-1 are under the transcriptional inﬂuence of
NFκB[ 33]. Chromatin modiﬁcations, such as histone lysine4 International Journal of Vascular Medicine
acetylation and arginine methylation, are key regulators
of NFκB activity. p65 protein is a key transcriptionally
active component of NFκB whose transactivation potential
is enhanced by several coactivators, including PCAF and
SRC1, which have histone acetyltransferase activity, and
CARM1, which has arginine methyltransferase activity [34].
Monomethylation of H3K4 (active transcription marker)
by the histone methyltransferase SET7 can regulate the
expression of a subset of key NFκB downstream proinﬂam-
matory genes, such as MCP-1 and IL-8, by interacting with
NFκB and modulating chromatin remodeling events at their
promoters [34]. SET7 short hairpin (sh) RNA blocked the
expression of proinﬂammatory genes in HEK-293 cells, as
w e l la sT H P - 1m o n o c y t e s .S E T 7m a yt h e r e f o r ea c ta sa
novel coactivator of proinﬂammatory genes, opening the
chromatin for enhanced transcription of a subset of NFκB-
dependent genes in diseases, such as atherosclerosis and
diabetes [34, 35].
4.4. Oxidative Stress. The oxidation-reduction state of the
cells is usually a balance between the generation of reactive
oxygenspecies(ROS)andthespeciﬁcmolecularmechanisms
to remove them. Once this equilibrium is in favor of higher
levels of ROS, it is a condition known as oxidative stress.
ROS include superoxide anion (O2
∗−), hydrogen perox-
ide (H2O2), hydroxyl radical (OH∗), hypochlorous acid
(HOCl), nitric oxide (NO), and peroxynitrite (ONOO
−).
ROS can be generated in a variety of cell types, including
SMC, EC, and mononuclear cells, and they are produced
byvariousoxidaseenzymes,includingnicotinamide-adenine
dinucleotidephosphate(NADPH)oxidase,xanthineoxidase,
uncoupled endothelial NO synthase (eNOS), cyclooxyge-
nase, glucose oxidase, and lipoxygenase, as well as via
mitochondrialelectrontransport.Cellsalsohaveantioxidant
mechanisms to protect themselves from the burden of ROS,
such as superoxide dismutase (SOD), glutathione peroxidase
(GPx), and catalases [36]. Enhanced oxidative stress has
been shown to be an exacerbating factor in pathologies
including inﬂammation, reperfusion injuries, and ageing
[37]. Uncoupling of eNOS in the endothelium may lead to
oxidative stress and endothelial dysfunction via numerous
mechanisms [38]. Firstly, the enzymatic production of NO
is diminished, allowing the radicals that it normally might
reactwithtoattackothercellulartargets.Second,theenzyme
begins to produce O2
∗−, contributing to oxidative stress.
Finally,itislikelythateNOScanbecomepartiallyuncoupled,
s u c ht h a tb o t hO 2
∗− and NO are produced simultaneously.
Under these circumstances, eNOS may become a peroxyni-
trite generator, leading to a dramatic increase in oxidative
stress [39].
Oxidation of LDL (oxLDL) produces minimally mod-
iﬁed LDL, which has been involved in promotion of
proatherosclerotic pathways [40]. Stimulation of HUVECs
with oxLDL time dependently induced global, as well as spe-
ciﬁc IL-8 and MCP-1 promoter acetylation of H4 and phos-
phorylation/acetylation of H3 at Ser-10/Lys-14, probably via
the LOX-1/ERK1/2 signaling pathway [40]. These eﬀects are
enhancedinthepresenceofHDACinhibitors. Preincubation
of cells with statins blocked oxLDL-related modiﬁcation of
H3 (Ser-10/Lys-14) as well as H4. These posttranscriptional
modiﬁcations were accompanied by recruitment of NFκB
p65/RelA and RNA polymerase II to the promoters [40].
In addition, exposure of vascular SMCs to oxidative stress
results in repression of the insulin-like growth factor 1
receptor (IGF1R), key receptor in the survival of many
cells, as a result of epigenetic modiﬁcations involving the
phosphorylation of p53 and its increased association with
HDAC1 [41].
4.5. Diabetes Mellitus. Diabetes mellitus is characterized by
accelerated atherosclerosis and higher risk for cardiovascular
diseases. The hyperglycemia associated with diabetes can
lead to modiﬁcations of macromolecules, for example, LDL,
by forming advanced glycation end products (AGE), which
can bind to surface receptors, such as RAGE (receptor for
AGEs) [42]. These AGE-modiﬁed proteins can augment
the production of proinﬂammatory cytokines and other
inﬂammatory pathways [6]. The diabetic state also promotes
oxidative stress and hyperglycemia, which increases the
expression of MCP-1 in EC and SMC [43]. Moreover, it
has been shown that high glucose levels promote foam cell
formation, not only in macrophages but also in human
cultured SMC [44].
InﬂammatorypathwayactivationinECandSMCbyhigh
glucose levels has been related to epigenetic modiﬁcations
[45, 46], and these modiﬁcations persisted after the return
of the EC to physiological levels of glucose [45]. Thus,
diabetescouldactivateinﬂammationpathwaysviaepigenetic
mechanisms.
5. Epigenetic Markers Linked to Atherosclerosis
Thestudyoftheepigeneticproﬁleassociatedwithproathero-
genic gene activation or silencing in the vasculature may
be complicated by the many distinct cell types involved in
the process, as well as their genetic background, not to
mention dietary and other environmental factors that could
be involved (Figure 3).
DNA methylation is an important epigenetic mechanism
that selectively regulates gene expression and is associated
with cardiovascular disease [47, 48]. Speciﬁc changes in
DNA methylation pattern occur prior the appearance of
vascular lesions in apoE
−/− mice, particularly in the aorta
and circulating inﬂammatory cells [49].
Theestrogenreceptorsαandβ(ERαandERβ)aresteroid
hormone receptors that can act as transcription factors,
both in vascular and nonvascular cells. ERα and ERβ are
important candidate genes to study epigenetic changes in
atherosclerosis and vascular ageing as they have classical
CpG islands in their promoter region, which can potentially
modulate estrogenic cardiovascular protective eﬀects [50].
HypermethylationofERβ wasobservedinsenescentvascular
EC and SMC as well as in atherosclerotic lesions.
Histone acetylation seems to have a signiﬁcant eﬀect on
atherogenesis. Choi et al. showed that TSA markedly exac-
erbated atherogenesis in hyperlipidemic mice, but without
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Figure 3: Factors such as nutritional status and genotype have been involved in the presence of risk factors, which not only activate
biochemical pathways that lead to cellular dysfunction, but also can alter epigenetics tags on DNA and Histone. The sum of epigenetic
modiﬁcations in the vascular cells will result in an atherosclerotic epigenetic proﬁle. ROS: reactive oxygen species; EC: endothelial cell; SMC:
smooth muscle cell; Mo/Ma: monocyte/macrophage.
mRNAs encoding CD36, SRA, TNF-alpha, and VCAM-1
was signiﬁcantly elevated in aortic homogenates, although
expression of MCP-1, IL-6, and IL-1 mRNA was decreased
[51]. Furthermore, the expression of CD36 and the uptake
of oxLDL were increased in a mouse monocyte-macrophage
cell line incubated with 1 to 10ng/ml of TSA.
HDAC2 is implicated in the transcriptional inactivation
of class II transactivator (CIITA), the transcriptional factor
responsible for collagen promoter repression (COL1A2) in
SMC and activation of Major Histocompatibility Complex ll
(MHCII)promoterinmacrophagesandSMC,inresponseto
IFN-γ [52]. HDAC2 interacts with and deacetylates CIITA,
targeting it to proteasomal degradation, and antagonizing
the transcriptional activity in macrophages and SMC. There-
fore, HDAC2 may delay the atherogenic process by blocking
T-cell activation and stabilizing the atherosclerotic plaque
[52].
HDAC3 expression is upregulated in EC in areas close
to branch openings where there is disturbed ﬂow. HDAC3
knocked down in EC had a dramatic eﬀect in vitro on EC
morphology and survival, probably through interaction with
Akt [51]. An in vivo mouse aortic isograft model was used to
study the eﬀect of HDAC3, and it conﬁrmed a prominent
role for the deacetylase enzyme in maintaining the integrity
of the vessel [53]. Moreover, HDAC3 siRNA decreased the
expression of VCAM-1 in endothelial cells and the adhesion
of monocytes [54].
In steady laminar ﬂow experiments, phosphorylation
of HDAC5 was stimulated both in HUVEC and bovine
aortic EC [55]. This phosphorylation was Ca2+/calmodulin
dependent and also promoted the export of HDAC5 from
the nucleus to the cytoplasm. The translocation of this
HDAC released the transcriptional factor MEF2C, which
could induce the expression of Kruppel like Factor 2 (KLF2),
considered as an atheroprotective transcription factor [55,
56].
6.Perspectives
Given that epigenetics could represent the link between
phenotype and genotype, it may be feasible to manipulate
the epigenetic marks targeting the enzymes responsible for
them to treat or prevent atherosclerosis, or at very least
these biomarkers could be used as a measure of individual
susceptibility to a given complication. There is evidence that
each of the major risk factors linked to the atherosclerotic
process has some degree of inﬂuence on the modulation of
epigenetic tags that can be found on the promoter regions of
transcription factors involved in the atherosclerotic process
(i.e., NFκB). It is the subsequent promotion or repression of
transcription that controls expression of downstream genes
in the associated pathway. Further studies should be directed
both to the activation of protective genes in EC and/or SMC
in sensitive zones of the vascular tree and the development
of gene-speciﬁc silencing therapy through the regulation of
cellular epigenetics.
References
[1] K. M. Morrison, S. A. Atkinson, S. Yusuf et al., “The Family
Atherosclerosis Monitoring In earLY life (FAMILY) study.
Rationale, design, and baseline data of a study examining
the early determinants of atherosclerosis,” American Heart
Journal, vol. 158, no. 4, pp. 533–539, 2009.6 International Journal of Vascular Medicine
[2] D. X.-F. Deng, J. M. Spin, A. Tsalenko et al., “Molecular
signatures determining coronary artery and saphenous vein
smooth muscle cell phenotypes: distinct responses to stimuli,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no.
5, pp. 1058–1065, 2006.
[3] D. Won, S.-N. Zhu, M. Chen et al., “Relative reduction of
endothelial nitric-oxide synthase expression and transcription
in atherosclerosis-prone regions of the mouse aorta and in
an in vitro model of disturbed ﬂow,” American Journal of
Pathology, vol. 171, no. 5, pp. 1691–1704, 2007.
[4] A. Bird, “Perceptions of epigenetics,” Nature, vol. 447, no.
7143, pp. 396–398, 2007.
[5] A. J. Lusis, “Atherosclerosis,” Nature, vol. 407, no. 6801, pp.
233–241, 2000.
[6] P. Libby, P. M. Ridker, and A. Maseri, “Inﬂammation and
atherosclerosis,” Circulation, vol. 105, no. 9, pp. 1135–1143,
2002.
[7] K. Iiyama, L. Hajra, M. Iiyama et al., “Patterns of vascular
cell adhesion molecule-1 and intercellular adhesion molecule-
1 expression in rabbit and mouse atherosclerotic lesions and
at sites predisposed to lesion formation,” Circulation Research,
vol. 85, no. 2, pp. 199–207, 1999.
[ 8 ]C .P .R e g a n ,P .J .A d a m ,C .S .M a d s e n ,a n dG .K .O w e n s ,
“Molecular mechanisms of decreased smooth muscle diﬀer-
entiation marker expression after vascular injury,” Journal of
Clinical Investigation, vol. 106, no. 9, pp. 1139–1147, 2000.
[9] C. Napoli, F. P. D’Armiento, F. P. Mancini et al., “Fatty
streak formation occurs in human fetal aortas and is greatly
enhanced bymaternalhypercholesterolemia. Intimalaccumu-
lation of low density lipoprotein and its oxidation precede
monocyte recruitment into early atherosclerotic lesions,”
Journal of Clinical Investigation, vol. 100, no. 11, pp. 2680–
2690, 1997.
[10] M. D. Shahbazian and M. Grunstein, “Functions of Site-
Speciﬁc histone acetylation and deacetylation,” Annual Review
of Biochemistry, vol. 76, pp. 75–100, 2007.
[11] C. D. Allis, T. Jenuwein, and D. Reinberg, “ Overview and
concepts,” in Epigenetics,C .D .A l l i s ,T .J e n u w e i n ,a n dD .
Reinberg, Eds., chapter 3, Cold Spring Harbor Laboratory
Press, Cold Spring Harbor, NY, USA, 2009.
[12] S. Pradhan, H. G. Chin, P. -O. Est` eve, and S. E. Jacobsen,
“SET7/9 mediated methylation of non-histone proteins in
mammalian cells,” Epigenetics, vol. 4, no. 6, pp. 383–387, 2009.
[13] W. Chen, M. Bacanamwo, and D. G. Harrison, “Activation of
p300 histone acetyltransferase activity is an early endothelial
responsetolaminarshearstressandisessentialforstimulation
of endothelial nitric-oxide synthase mRNA transcription,”
Journal of Biological Chemistry, vol. 283, no. 24, pp. 16293–
16298, 2008.
[14] A. V. Bieliauskas and M. K. H. Pﬂum, “Isoform-selective
histone deacetylase inhibitors,” Chemical Society Reviews, vol.
37, no. 7, pp. 1402–1413, 2008.
[15] K. Garber, “HDAC inhibitors overcome ﬁrst hurdle,” Nature
Biotechnology, vol. 25, no. 1, pp. 17–19, 2007.
[16] A. Karytinos, F. Forneris, A. Profumo et al., “A novel
mammalianﬂavin-dependenthistonedemethylase,”Journalof
Biological Chemistry, vol. 284, no. 26, pp. 17775–17782, 2009.
[17] M.G.GollandT.H.Bestor,“Eukaryoticcytosinemethyltrans-
ferases,” Annual Review of Biochemistry, vol. 74, pp. 481–514,
2005.
[18] X. Wang, N. Ishimori, R. Korstanje, J. Rollins, and B. Paigen,
“Identifying novel genes for atherosclerosis through mouse-
human comparative genetics,” American Journal of Human
Genetics, vol. 77, no. 1, pp. 1–16, 2005.
[19] D. Shiftman, S. G. Ellis, C. M. Rowland et al., “Identiﬁcation
of four gene variants associated with myocardial infarction,”
American Journal of Human Genetics, vol. 77, no. 4, pp. 596–
605, 2005.
[20] D. A. H¨ agg, M. Jern˚ as, O. Wiklund et al., “Expression proﬁling
of macrophages from subjects with atherosclerosis to identify
novel susceptibility genes,” International Journal of Molecular
Medicine, vol. 21, no. 6, pp. 697–704, 2008.
[21] D. Steinberg, “An interpretive history of the cholesterol
controversy, part III: mechanistically deﬁning the role of
hyperlipidemia,” Journal of Lipid Research, vol. 46, no. 10, pp.
2037–2051, 2005.
[22] C. R. Sirtori and R. Fumagalli, “LDL-cholesterol lowering
or HDL-cholesterol raising for cardiovascular prevention:
a lesson from cholesterol turnover studies and others,”
Atherosclerosis, vol. 186, no. 1, pp. 1–11, 2006.
[23] F. E. Alkemade, P. Van Vliet, P. Henneman et al., “Pre-
natal Exposure to apoE deﬁciency and postnatal hyperc-
holesterolemia are associated with altered cell-speciﬁc lysine
methyltransferase and histone methylation patterns in the
vasculature,”AmericanJournalofPathology,vol.176,no.2,pp.
542–548, 2010.
[24] L. Brattstrom and D. E. L. Wilcken, “Homocysteine and
cardiovascular disease: cause or eﬀect?” American Journal of
Clinical Nutrition, vol. 72, no. 2, pp. 315–323, 2000.
[25] J. Joseph, D. E. Handy, and J. Loscalzo, “Quo vadis: whiter
homocysteine research?” Cardiovascular Toxicology, pp. 1–11,
2009.
[ 2 6 ]R .d eF r a n c h i s ,I .F e r m o ,G .M a z z o l ae ta l . ,“ C o n t r i b u t i o no f
the cystathionine β-synthase gene (844ins68) polymorphism
to the risk of early-onset venous and arterial occlusive
disease and of fasting hyperhomocysteinemia,” Thrombosis
and Haemostasis, vol. 84, no. 4, pp. 576–582, 2000.
[27] M. Gaustadnes, N. R¨ udiger, K. Rasmussen, and J. Inger-
slev, “Intermediate and severe hyperhomocysteinemia with
thrombosis: a study of genetic determinants,” Thrombosis and
Haemostasis, vol. 83, no. 4, pp. 554–558, 2000.
[28] M. G. Andreassi, N. Botto, F. Cocci et al., “Methylenete-
trahydrofolate reductase gene C677T polymorphism, homo-
cysteine, vitamin B12, and DNA damage in coronary artery
disease,” Human Genetics, vol. 112, no. 2, pp. 171–177, 2003.
[29] J. Yideng, Z. Jianzhong, H. Ying et al., “Homocysteine-
mediated expression of SAHH, DNMTs, MBD2, and DNA
hypomethylation potential pathogenic mechanism in
VSMCs,” DNA and Cell Biology, vol. 26, no. 8, pp. 603–611,
2007.
[30] M. S. Jamaluddin, I. Chen, F. Yang et al., “Homocysteine
inhibits endothelial cell growth via DNA hypomethylation of




and its potential pathogenic mechanism in monocytes,” DNA
and Cell Biology, vol. 27, no. 3, pp. 143–150, 2008.
[32] A. Bowie and L. A. J. O’Neill, “Oxidative stress and nuclear
factor-κBactivation:areassessmentoftheevidenceinthelight
of recent discoveries,” Biochemical Pharmacology, vol. 59, no.
1, pp. 13–23, 2000.
[33] P. J. Barnes and M. Karin, “Nuclear factor-κB—a pivotal
transcription factor in chronic inﬂammatory diseases,” New
England Journal of Medicine, vol. 336, no. 15, pp. 1066–1071,
1997.
[34] Y. Li, M. A. Reddy, F. Miao et al., “Role of the histone
H3 lysine 4 methyltransferase, SET7/9, in the regulation ofInternational Journal of Vascular Medicine 7
NF-κB-dependent inﬂammatory genes: relevance to diabetes
and inﬂammation,” Journal of Biological Chemistry, vol. 283,
no. 39, pp. 26771–26781, 2008.
[35] D. Brasacchio, J. Okabe, C. Tikellis et al., “Hyperglycemia
induces a dynamic cooperativity of histone methylase and
demethylase enzymes associated with gene-activating epige-
netic marks that coexist on the lysine tail,” Diabetes, vol. 58,
no. 5, pp. 1229–1236, 2009.
[36] Y. Higashi, K. Noma, M. Yoshizumi, and Y. Kihara, “Endothe-
lial function and oxidative stress in cardiovascular diseases,”
Circulation Journal, vol. 73, no. 3, pp. 411–418, 2009.
[37] I. Fridovich, “Oxidative stress,” in Encyclopedia of Life Sciences
(ELS), John Wiley & Sons, Chichester, UK, 2009.
[38] H. Cai and D. G. Harrison, “Endothelial dysfunction in
cardiovascular diseases: the role of oxidant stress,” Circulation
Research, vol. 87, no. 10, pp. 840–844, 2000.
[39] U. Singh and I. Jialal, “Oxidative stress and atherosclerosis,”
Pathophysiology, vol. 13, no. 3, pp. 129–142, 2006.
[40] P. D. N’Guessan, F. Riediger, K. Vardarova et al., “Statins
control oxidized ldl-mediated histone modiﬁcations and gene
expression in cultured human endothelial cells,” Arteriosclero-
sis, Thrombosis, and Vascular Biology, vol. 29, no. 3, pp. 380–
386, 2009.
[ 4 1 ]M .M .K a v u r m a ,N .F i g g ,M .R .B e n n e t t ,J .M e r c e r ,L .M .
Khachigian, and T. D. Uttlewood, “Oxidative stress regulates
IGF1R expression in vascular smooth-muscle cells via p53 and
HDAC recruitment,” Biochemical Journal, vol. 407, no. 1, pp.
79–87, 2007.
[42] C. P. Hodgkinson, R. C. Laxton, K. Patel, and S. Ye, “Advanced
glycation end-product of low density lipoprotein activates
the toll-like 4 receptor pathway implications for diabetic
atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular
Biology, vol. 28, no. 12, pp. 2275–2281, 2008.
[43] E. Dragomir and M. Simionescu, “Monocyte chemoattractant
protein-1—a major contributor to the inﬂammatory process
associated with diabetes,” Archives of Physiology and Biochem-
istry, vol. 112, no. 4-5, pp. 239–244, 2006.
[44] J.-H. Xue, Z. Yuan, Y. Wu et al., “High glucose promotes
intracellular lipid accumulation in vascular smooth muscle
cells by impairing cholesterol inﬂux and eﬄux balance,”
Cardiovascular Research, vol. 86, no. 1, pp. 141–150, 2010.
[45] A. El-Osta, D. Brasacchio, D. Yao et al., “Transient high
glucose causes persistent epigenetic changes and altered gene
expression during subsequent normoglycemia,” Journal of
Experimental Medicine, vol. 205, no. 10, pp. 2409–2417, 2008.
[ 4 6 ]L .M .V i l l e n e u v e ,M .A .R e d d y ,L .L .L a n t i n g ,M .W a n g ,L .
Meng, and R. Natarajan, “Epigenetic histone H3 lysine 9
methylation in metabolic memory and inﬂammatory pheno-
type of vascular smooth muscle cells in diabetes,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 105, no. 26, pp. 9047–9052, 2008.
[47] M.O.Laukkanen,S.Mannermaa,M.O.Hiltunenetal.,“Local
hypomethylation in atherosclerosis found in rabbit ec-sod
gene,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol.
19, no. 9, pp. 2171–2178, 1999.
[48] M. O. Hiltunen and S. Yl¨ a-Herttuala, “DNA methylation,
smooth muscle cells, and atherogenesis,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 23, no. 10, pp. 1750–
1753, 2003.
[49] G. Lund, L. Andersson, M. Lauria et al., “DNA methylation
polymorphisms precede any histological sign of atheroscle-
rosis in mice lacking apolipoprotein E,” Journal of Biological
Chemistry, vol. 279, no. 28, pp. 29147–29154, 2004.
[50] J.Kim,J.Y.Kim,K.S.Songetal.,“Epigeneticchangesinestro-
gen receptor β gene in atherosclerotic cardiovascular tissues
and in-vitro vascular senescence,” Biochimica et Biophysica
Acta, vol. 1772, no. 1, pp. 72–80, 2007.
[51] J.-H. Choi, K.-H. Nam, J. Kim et al., “Trichostatin A exac-
erbates atherosclerosis in low density lipoprotein receptor-
deﬁcient mice,” Arteriosclerosis, Thrombosis, and Vascular
Biology, vol. 25, no. 11, pp. 2404–2409, 2005.
[52] X. Kong, M. Fang, P. Li, F. Fang, and Y. Xu, “HDAC2
deacetylates class II transactivator and suppresses its activity
inmacrophagesandsmoothmusclecells,”JournalofMolecular
and Cellular Cardiology, vol. 46, no. 3, pp. 292–299, 2009.
[53] A. Zampetaki, L. Zeng, A. Margariti et al., “Histone deacety-
lase 3 is critical in endothelial survival and atherosclerosis
development in response to disturbed ﬂow,” Circulation, vol.
121, no. 1, pp. 132–142, 2010.
[54] K. Inoue, M. Kobayashi, K. Yano et al., “Histone deacetylase
inhibitor reduces monocyte adhesion to endothelium through
the suppression of vascular cell adhesion molecule-1 expres-
sion,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol.
26, no. 12, pp. 2652–2659, 2006.
[55] W. Wang, C. H. Ha, B. S. Jhun, C. Wong, M. K. Jain, and Z.-G.
Jin, “Fluid shear stress stimulates phosphorylation-dependent
nuclear export of HDAC5 and mediates expression of KLF2
and eNOS,” Blood, vol. 115, no. 14, pp. 2971–2979, 2010.
[56] G. B. Atkins, Y. Wang, G. H. Mahabeleshwar et al., “Hemizy-
gous deﬁciency of kr¨ uppel-like factor 2 augments experimen-
tal atherosclerosis,” Circulation Research, vol. 103, no. 7, pp.
690–693, 2008.